Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 212

1.

Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy.

Morgans AK, Smith MR, O'Malley AJ, Keating NL.

Cancer. 2013 Feb 15;119(4):863-70. doi: 10.1002/cncr.27830. Epub 2012 Oct 12.

2.

Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer.

Shahinian VB, Kuo YF.

J Gen Intern Med. 2013 Nov;28(11):1440-6. doi: 10.1007/s11606-013-2477-2. Epub 2013 May 14.

3.

Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.

Shao YH, Moore DF, Shih W, Lin Y, Jang TL, Lu-Yao GL.

BJU Int. 2013 May;111(5):745-52. doi: 10.1111/j.1464-410X.2012.11758.x. Epub 2013 Jan 17.

4.

Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study.

Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Stanford JL, Stroup AM, Penson DF.

Prostate Cancer Prostatic Dis. 2014 Dec;17(4):338-42. doi: 10.1038/pcan.2014.31. Epub 2014 Aug 19.

5.

Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapy.

Suarez-Almazor ME, Peddi P, Luo R, Nguyen HT, Elting LS.

Support Care Cancer. 2014 Feb;22(2):537-44. doi: 10.1007/s00520-013-2008-z. Epub 2013 Oct 22.

6.

Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

Kiratli BJ, Srinivas S, Perkash I, Terris MK.

Urology. 2001 Jan;57(1):127-32.

PMID:
11164157
7.

Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.

Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM.

J Clin Endocrinol Metab. 2005 Dec;90(12):6410-7. Epub 2005 Sep 27.

PMID:
16189261
8.

Androgen deprivation in veterans with prostate cancer: implications for skeletal health.

Wilcox A, Carnes ML, Moon TD, Tobias R, Baade H, Stamos E, Elliott ME.

Ann Pharmacother. 2006 Dec;40(12):2107-14. Epub 2006 Nov 28.

PMID:
17132807
9.

Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D.

Alibhai SM, Mohamedali HZ, Gulamhusein H, Panju AH, Breunis H, Timilshina N, Fleshner N, Krahn MD, Naglie G, Tannock IF, Tomlinson G, Warde P, Duff Canning S, Cheung AM.

Osteoporos Int. 2013 Oct;24(10):2571-9. doi: 10.1007/s00198-013-2343-4. Epub 2013 Apr 6.

PMID:
23563932
10.

Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.

Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS; Urologic Diseases in America Project.

Cancer. 2007 Oct 1;110(7):1493-500.

11.

Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.

Krupski TL, Smith MR, Lee WC, Pashos CL, Brandman J, Wang Q, Botteman M, Litwin MS.

Cancer. 2004 Aug 1;101(3):541-9. Erratum in: Cancer. 2004 Nov 15;101(10):2370.

12.

Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.

Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR.

Cancer. 2004 Mar 1;100(5):892-9. Review.

13.

Use of androgen deprivation therapy for metastatic prostate cancer in older men.

Keating NL, O'Malley AJ, McNaughton-Collins M, Oh WK, Smith MR.

BJU Int. 2008 May;101(9):1077-83. doi: 10.1111/j.1464-410X.2007.07405.x. Epub 2008 Jan 8.

14.

Androgen deprivation therapy for prostate cancer results in significant loss of bone density.

Wei JT, Gross M, Jaffe CA, Gravlin K, Lahaie M, Faerber GJ, Cooney KA.

Urology. 1999 Oct;54(4):607-11.

PMID:
10510915
15.

Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.

Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.

Prostate Cancer Prostatic Dis. 2002;5(4):304-10.

16.

Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer.

Ito K, Elkin EB, Girotra M, Morris MJ.

Ann Intern Med. 2010 May 18;152(10):621-9. doi: 10.7326/0003-4819-152-10-201005180-00002.

17.

Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer.

Morgans AK, Hancock ML, Barnette KG, Steiner MS, Morton RA, Smith MR.

J Urol. 2012 Mar;187(3):889-93. doi: 10.1016/j.juro.2011.10.136. Epub 2012 Jan 15.

18.

Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer.

Panju AH, Breunis H, Cheung AM, Leach M, Fleshner N, Warde P, Duff-Canning S, Krahn M, Naglie G, Tannock I, Tomlinson G, Alibhai SM.

BJU Int. 2009 Mar;103(6):753-7. doi: 10.1111/j.1464-410X.2008.08156.x. Epub 2008 Oct 24.

19.

Long-term effects of androgen deprivation therapy in prostate cancer patients.

Basaria S, Lieb J 2nd, Tang AM, DeWeese T, Carducci M, Eisenberger M, Dobs AS.

Clin Endocrinol (Oxf). 2002 Jun;56(6):779-86.

PMID:
12072048
20.

Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer.

Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL.

JAMA Intern Med. 2014 Sep;174(9):1460-7. doi: 10.1001/jamainternmed.2014.3028.

Supplemental Content

Support Center